Document is current
Any future updates will be listed below
-
Authors
Zhang, Yue
Du, Mingxia
Wang, Yi-Han
Li, Min
Jin, Kangxin
Pan, Deng
Zhang, Xiao
Jin, Zi-Bing
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82201225)
National Natural Science Foundation of China (82125007)
Beijing Municipal Science & Technology Commission (Z231100007223005)
Beijing Natural Science Foundation (Z200014)
Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support (DFL20220202)
Excellent Clinical Research Program (BRWEP2024W172050100)
Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes (PWD&RPP-MRI)
Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes (JYY2023-6)
- License Information
-
More Information
Article History
Received: 24 October 2025
Accepted: 12 April 2026
First Online: 30 April 2026
Declarations
:
: The human embryonic stem cell (hESC) lines used in this study, along with all related genetic modifications, were derived in full compliance with ethical guidelines and under the approval of the Ethics Committee of Beijing Tongren Hospital, Capital Medical University (guidelines of the Declaration of Helsinki). The approving project was titled “Development of in vitro disease models for hereditary eye diseases” (Approval number: TREC2021-088; Date of approval: April 22, 2021).
: The authors declare no competing interests.
